| Description | Bederocin (REP8839)is a novel inhibitor of methionyl tRNA synthase (METS) with potent antibacterial activity against clinical isolates of Staphylococcus aureus, Streptococcus pyogenes, and other clinically important Gram-positive bacteria. |
| Target activity | MetRS:0.01 µM(Ki) |
| Synonyms | REP 8839, REP-8839, REP8839 |
| molecular weight | 450.37 |
| Molecular formula | C20H21BrFN3OS |
| CAS | 757942-43-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Hussain T, et al. Inhibition of protein synthesis and malaria parasite development by drug targeting of methionyl-tRNA synthetases. Antimicrob Agents Chemother. 2015 ; 59(4):1856-1867. 2. Faqi AS, et al. An intranasal irritation assessment of antibacterial ointment alone or in combination with mupirocin versus Bactroban Nasal in rabbits. Regul Toxicol Pharmacol. 2009 ; 55(1):28-32. 3. Green LS, et al. Inhibition of methionyl-tRNA synthetase by REP8839 and effects of resistance mutations on enzyme activity. Antimicrob Agents Chemother. 2009 ; 53(1):86-94. 4. Critchley IA, et al. Recent advances in the preclinical evaluation of the topical antibacterial agent REP8839. Curr Opin Chem Biol. 2008 ; 12(4):409-417. |